

OVERVIEW

As part of the BPCA mandate, six public assemblies have been convened to develop a generic framework to provide an overall structure to enable pediatric drug development studies. The goal is to develop -- in collaboration with subject matter experts (SMEs) in pediatric care and research -- an annotated, selective, curated collection of resources that will assist drug developers, researchers, and clinicians conducting pediatric drug development research. As part of this process, assembly participants are asked to submit references for best practice and guidance documents for inclusion in the final framework. This online form has been created to streamline this process.

BPCA Framework to Enable Pediatric Drug Development Resource Submission Form OMB# 0925-0766 Exp Date: 4/2023

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.



All submissions must be available in the public domain. All submissions will be compiled and shared with assembly participants for eventual inclusion in the final framework.


Multiple submissions are welcome but you must submit them individually. You may complete this form as many times as you'd like.

*	Which category best applies to your framework submission?
	General/Overview
	Advancing Clinical Trials
	Biomarkers
	Systems Pharmacology
	Pediatric-Friendly Formulations
	Pharmacoepidemiology
	PK Modeling to Inform Dosing



Skip Logic Note: This question is only shown if General/Overview is selected for the first question.						
* Which sub-category does your GENERAL DRUG DEVELOPMENT submission fall under?						
General Drug Development Overview (principles that apply across all populations)						
Pediatric Drug Development Overview (including extrapolation, iPSPs)						







Pre-clinical/drug	discovery		
Dosing			



kip Logic Note: This question is only shown if Pharmacoepidemiology is selected for the first question. What sub-category does your PHARMACOEPIDEMIOLOGY submission fall under? Pharmacoepidemiology studies including post-authorization	
Real-world data	



* The final framework will include resources in the areas below. Which option best applies to your submission?					
Read this First (single document 10 - 20 pages that give an overview)					
This is a Helpful Explanation					
U.S. Guidance					
Non-U.S. Guidance					
Please list the title and reference of your submission below, along with your name, email address, and any comments you may have. REMINDER: All submissions must be available in the public domain.					
* Title/Description					
* Weblink/Reference					
Name					
Email Address					

Comments	
**	



Thank you for your submission! If you would like to submit another reference, please click <u>here</u>.

Questions? Contact bpca@infinityconferences.com.